Trial Profile

Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) / Human Acellular Vessel (HAV)

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 25 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Human acellular vessel-Humacyte (Primary)
Indications Cardiovascular disorders; Congenital heart defects; Ischaemia; Renal failure; Type 1 diabetes mellitus; Vascular injuries
Focus Expanded access; Therapeutic Use
Sponsors Humacyte

Most Recent Events

21 Mar 2025 Status changed from recruiting to completed.
29 Jun 2022 According to a Humacyte media release, data from the first series of compassionate use cases of the HAV for the treatment of critical limb ischemia from this study were also recently published online in the Annals of Vascular Surgery.
31 Jan 2022 Results published in the Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com